Duchenne Muscular Dystrophy (DMD)

New Forms of Genetic Testing Improve Diagnosis, Raise Questions

“Knowing, if not all, is almost all,” said Matthew Harms, a neurologist and neurophysiologist from Washington University in St. Louis, in his presentation on genetic testing for neuromuscular disorders at the 2014 MDA Clinical Conference, held in Chicago March 16-19.

Shooting for Hope

Artist: 

Bryson is an honor roll student at school. His favorite subjects are reading, spelling and social studies, but sports are his true passion. He collects sports memorabilia. Bryson served two years as MDA’s National Goodwill Ambassador from 2011 – 2013. He and his parents traveled throughout the United States attending events, meeting with sponsors and spreading the message of MDA’s mission. He appeared on the Labor Day Telethon as a co-announcer for two years.

DMD: Phase 2 Drisapersen Results Encouraging

DMD, BMD: Ataluren Did Not Receive Early Approval in Europe

PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy

DMD: What's Next for Drisapersen?

Eteplirsen Data Still Strong: Treated Boys with DMD Stable at 120 Weeks

DMD: Prosensa to Present Webcasts on Drug Development

Dutch biopharmaceutical company Prosensa, developer of the experimental drug drisapersen and other experimental compounds for Duchenne muscular dystrophy (DMD), will update the investor community via a Thursday, Jan. 16, 2014, presentation at the J.P. Morgan Healthcare Conference in San Francisco. The presentation will be webcast at 10 a.m. Pacific time/1 p.m. Eastern time.

On Tuesday, Jan. 21, at 8 a.m. Eastern time, Prosensa will conduct a separate webinar for DMD patients and families.

DMD: GSK Returns Drisapersen Development Rights to Prosensa

The rights to development of the experimental Duchenne muscular dystrophy (DMD) drisapersen have now been returned to the drug's original developer, Dutch biotechnology company Prosensa. The rights were formerly jointly held by Prosensa and multinational pharmaceutical company GlaxoSmithKline (GSK).

College Course on DMD Available Online

A course on Duchenne muscular dystrophy (DMD), geared toward graduate and upper-division undergraduate students and held at Ohio State University College of Medicine and Nationwide Children's Hospital in Columbus, is open to the public, without charge, via real-time streaming and podcasts.

Pages